AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/article-1G1-179350294/affitech-oslo-norway-said.html" title="Facts and information about Affitech AS, of Oslo, Norway, said preclinical studies demonstrated that PGN635, a fully human antibody developed through a collaboration with Peregrine Pharmaceuticals, of Tustin, Calif., exhibits antitumor efficacy by targeting phosphatidylserine (PS).(Other News To Note)">Affitech AS, of Oslo, Norway, said preclinical studies demonstrated that PGN635, a fully human antibody developed through a collaboration with Peregrine Pharmaceuticals, of Tustin, Calif., exhibits antitumor efficacy by targeting phosphatidylserine (PS).(Other News To Note)</a>

Close Set up an RSS feed that alerts you when new articles from BioWorld International are available.

Frequently asked questions about RSS feeds

Affitech AS, of Oslo, Norway, said preclinical studies demonstrated that PGN635, a fully human antibody developed through a collaboration with Peregrine Pharmaceuticals, of Tustin, Calif., exhibits antitumor efficacy by targeting phosphatidylserine (PS).(Other News To Note)

BioWorld International

| May 14, 2008 | COPYRIGHT 2003 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

Affitech AS, of Oslo, Norway, said preclinical studies demonstrated that PGN635, a fully human antibody developed through a collaboration with Peregrine Pharmaceuticals, of Tustin, Calif., exhibits antitumor efficacy by targeting phosphatidylserine (PS). Peregrine currently has an anti-PS antibody, bavituximab, which is in Phase II trials for the treatment of breast and lung cancers and in a Phase I study for …

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


Affitech-Identified Fully Human Anti-VEGF Antibody Candidate is as Effective as...: Press release article from: Business Wire November 19, 2007 700+ words
...preclinical results reported by Peregrine Pharmaceuticals represent an important...today that its partner, Peregrine Pharmaceuticals, has reported that its...Officer of Affitech. "The studies demonstrated that the selective blocking...

For more facts and information, see all results

Source: HighBeam Research, Affitech AS, of Oslo, Norway, said preclinical studies demonstrated...

The AccessMyLibrary advertising network includes: